Synchron, a brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, announced the acquisition of an equity stake in Acquandas, a leading technology provider specializing in state-of-the-art high-precision components for the healthcare industry and other industries.

As part of the transaction, Tom Oxley, Synchron’s CEO and founder, will join the Acquandas Governance Council and Riki Banerjee, Synchron’s CTO, will join as observer.

Synchron is a neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and autonomy for individuals with motor impairment.

“As we pioneer functional endovascular neurotechnology, this investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces,” says Oxley.

“After many years of development in fabrication technology, I am thrilled to welcome Synchron on board as an investor. This major investment will not only strengthen our existing partnership but will also play a pivotal role in expanding our facilities and capabilities. It serves as a testament to the readiness of our fabrication technology and our company for the market,” says CEO and Founder Dr Rodrigo Lima de Miranda, Acquandas.

Acquandas has established an entirely new generation of shape-memory, flexible metallic components suitable for use as medical devices. Their capability to manufacture miniaturized structures, such as micro-patterned Nitinol thin films, combined with high structure resolution and geometrical complexity, enhanced biocompatibility, and improved mechanical properties, provides Synchron with a distinctive product offering in the implantable medical device industry, according to the company.

Featured image: The Stentrode Endovascular Electrode Array. Photo: Synchron